Cart
sales@molnova.com
4-(6,7-dimethoxyquinolin-4-yl)oxyaniline
CAS No. 190728-25-7
4-(6,7-dimethoxyquinolin-4-yl)oxyaniline( 4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenylamine | BenzenaMine, 4-[(6,7-diMethoxy-4-quinolinyl)oxy]- )
Catalog No. M28615 CAS No. 190728-25-7
4-(6,7-dimethoxyquinolin-4-yl)oxyanilines is a chemical compound.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 25MG | 44 | In Stock |
|
| 50MG | 63 | In Stock |
|
| 100MG | 96 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 244 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name4-(6,7-dimethoxyquinolin-4-yl)oxyaniline
-
NoteResearch use only, not for human use.
-
Brief Description4-(6,7-dimethoxyquinolin-4-yl)oxyanilines is a chemical compound.
-
Description4-(6,7-dimethoxyquinolin-4-yl)oxyanilines is a chemical compound.
-
In Vitro——
-
In Vivo——
-
Synonyms4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenylamine | BenzenaMine, 4-[(6,7-diMethoxy-4-quinolinyl)oxy]-
-
PathwayOthers
-
TargetOther Targets
-
RecptorTLR7
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number190728-25-7
-
Formula Weight296.32
-
Molecular FormulaC17H16N2O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCOc(cc1c(Oc(cc2)ccc2N)ccnc1c1)c1OC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Saroa R, et al. Efficacy of TLR7 agonistic imidazoquinoline as immunochemotherapeutic agent against P. Berghei ANKA infected rodent host. Bioorg Med Chem Lett. 2019 May 1;29(9):1099-1105.
molnova catalog
related products
-
Fibrinogen β-Chain (...
Fibrinogen β-Chain (24-42)
-
MMP-8 Substrate, flu...
MMP-8/MMP-26 Fluorogenic substrate (DNP-Pro-Leu-Ala-Tyr-Trp-Ala-Arg) is a matrix metalloproteinase-8 (MMP-8) fluorogenic substrate. MMP-8/MMP-26 Fluorogenic substrate can be used for the research of atherosclerosis, pulmonary fibrosis, and sepsis.
-
BMS986260
BMS-986260 is a selective, and orally bioavailable TGFβR1 inhibitor(IC50 = 1.6 nM). BMS-986260?demonstrated functional activity in multiple TGFβ-dependent cellular assays, excellent kinome selectivity, favorable pharmacokinetic properties, and curative in vivo efficacy in combination with anti-PD-1 antibody in murine colorectal cancer (CRC) models.?
